A Registry Study of Biomarkers in Progression of Acute Heart Failure(BIOMS-POAHF)
NCT ID: NCT04108182
Last Updated: 2019-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
850 participants
OBSERVATIONAL
2015-12-31
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Registry Study of Biomarkers in Heart Failure
NCT03784833
Study of China Heart Failure Registry to Investigate Characteristics of Patients in China
NCT02664818
Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction
NCT05496439
Prognostic and Diagnostic Value of Biomarkers and Cardiac Functional Parameters in Patients With Chronic Heart Failure
NCT02776384
Biomarkers for Prognosis of Ambulatory Chronic Heart Failure Patients
NCT01113866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. With typical symptoms of acute heart failure as follows: Dyspnea, ankle swelling and fatigue (Limited activity endurance), increased jugular pressure, rales and peripheral edema ;
* 3\. Plasma concentrations of BNP: BNP\>100pg/ML
* 4\. Echocardiography: Related structural heart disease (left ventricular hypertrophy and/or left atrial enlargement) and/or diastolic dysfunction
Exclusion Criteria
* 2.Surgery was performed within a month
* 3.Accompanied by cardiogenic shock, sepsis, pneumonia
* 4.Eligible patients without informed consent form
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Institute of Heart, Lung and Blood Vessel Diseases
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jie Du, PHD
Role: STUDY_DIRECTOR
Beijing Anzhen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Anzhen Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ma K, Yang J, Shao Y, Li P, Guo H, Wu J, Zhu Y, Zhang H, Zhang X, Du J, Li Y. Therapeutic and Prognostic Significance of Arachidonic Acid in Heart Failure. Circ Res. 2022 Apr;130(7):1056-1071. doi: 10.1161/CIRCRESAHA.121.320548. Epub 2022 Mar 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIOMS-POAHF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.